Today’s Solutions: April 21, 2024

Just over a year ago, we shared an article about how Moderna is using mRNA technology to develop an HIV vaccine. Last week, the Phase I clinical trials for this very vaccine began.

The company is conducting the trial in partnership with the nonprofit International AIDS Vaccine Initiative (IAVI) and hopes that the trial will confirm whether the vaccine can deliver HIV-specific antigens to the body to induce an immune response.

The 56 HIV-negative adult volunteers will be under the watchful eye of the researchers for six months. During the study, 48 of the participants will receive at least one dose of the primary vaccine, and 32 out of these 48 will also receive the booster. The remaining eight will receive only the booster vaccine.

“We are tremendously excited to be advancing this new direction in HIV vaccine design with Moderna’s mRNA platform,” said the president and CEO of IAVI Mark Feinberg in a statement. “The search for an HIV vaccine has been long and challenging and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine.”

Solutions News Source Print this article
More of Today's Solutions

3 simple ways to save an extra $250 per month

Everyone loves to save money, so here are three easy ways you can free up $250 in your budget per month. Cancel subscriptions you ...

Read More

APA, AAPI, APIDA or AANHPI? The history and significance of the “Asian Americ...

“The journey of a thousand miles begins with one step.” ― Lao Tzu By Arielle Tiangco Weeks ago, seated cross-legged on my couch, I ...

Read More

Playing video games benefit key regions of the brain

A recent study from Georgia State University found that sensorimotor decision-making skills were superior in regular video game players to those that didn’t play ...

Read More

Novel blood cancer treatment effective in three-fourths of trial patients

According to new findings from an ongoing Phase 1/2 clinical research trial, a novel investigational immunotherapy resulted in successful response rates for 73 percent ...

Read More